Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Encircling the regions of the pharmacogenomic landscape that determine drug response

  • Fernández Torras, Adrià
  • Duran-Frigola, Miquel, 1985-
  • Aloy, Patrick, 1972-
Background: The integration of large-scale drug sensitivity screens and genome-wide experiments is changing the field of pharmacogenomics, revealing molecular determinants of drug response without the need for previous knowledge about drug action. In particular, transcriptional signatures of drug sensitivity may guide drug repositioning, prioritize drug combinations, and point to new therapeutic biomarkers. However, the inherent complexity of transcriptional signatures, with thousands of differentially expressed genes, makes them hard to interpret, thus giving poor mechanistic insights and hampering translation to clinics. Methods: To simplify drug signatures, we have developed a network-based methodology to identify functionally coherent gene modules. Our strategy starts with the calculation of drug-gene correlations and is followed by a pathway-oriented filtering and a network-diffusion analysis across the interactome. Results: We apply our approach to 189 drugs tested in 671 cancer cell lines and observe a connection between gene expression levels of the modules and mechanisms of action of the drugs. Further, we characterize multiple aspects of the modules, including their functional categories, tissue-specificity, and prevalence in clinics. Finally, we prove the predictive capability of the modules and demonstrate how they can be used as gene sets in conventional enrichment analyses. Conclusions: Network biology strategies like module detection are able to digest the outcome of large-scale pharmacogenomic initiatives, thereby contributing to their interpretability and improving the characterization of the drugs screened., A.F-T. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R) and the European Research Council (SysPharmAD: 614944).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel, 1985-
  • Gris-Oliver, Albert
  • Palafox, Marta
  • Scaltriti, Maurizio
  • Razavi, Pedram
  • Chandarlapaty, Sarat
  • Arribas, Joaquín
  • Bellet, Meritxell
  • Serra, Violeta
  • Aloy, Patrick, 1972-
Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients' progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling., Funding: L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the Generalitat de Catalunya (VEIS 001-P-001). V.S. is a recipient of a Miguel Servet grant from ISCIII (CPII19/00033) and receives funds from AGAUR (2017 SGR 540). The PDX program is supported by a GHD-Pink (FERO foundation) grant to V.S., A.G.-O. and M.P. received a FI-AGAUR and a Juan de la Cierva (MJCI-2015-25412) fellowship, respectively. M.S., P.R., and S.C. acknowledge the support of the NIH grants P30 CA008748, RO1CA190642
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

In silico characterization of human prion-like proteins: beyond neurological diseases

  • Iglesias, Valentin
  • Paladin, Lisanna
  • Juan Blanco, Teresa, 1989-
  • Pallarès, Irantzu
  • Aloy, Patrick, 1972-
  • Tosatto, Silvio C.E.
  • Ventura, Salvador
Prion-like behavior has been in the spotlight since it was first associated with the onset of mammalian neurodegenerative diseases. However, a growing body of evidence suggests that this mechanism could be behind the regulation of processes such as transcription and translation in multiple species. Here, we perform a stringent computational survey to identify prion-like proteins in the human proteome. We detected 242 candidate polypeptides and computationally assessed their function, protein-protein interaction networks, tissular expression, and their link to disease. Human prion-like proteins constitute a subset of modular polypeptides broadly expressed across different cell types and tissues, significantly associated with disease, embedded in highly connected interaction networks, and involved in the flow of genetic information in the cell. Our analysis suggests that these proteins might play a relevant role not only in neurological disorders, but also in different types of cancer and viral infections., SV was supported by Ministerio de Economía y Competitividad (MINECO) (BIO2016-78310-R) and by ICREA, ICREA ACADEMIA 2015 to SV. PA was supported by MINECO (BIO2016-77038-R) and the European Research Council Consolidator grant, SysPharmAD (614944). TJ-B is a recipient of an FPI-SO fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Bioactivity descriptors for uncharacterized chemical compounds

  • Bertoni, Martino
  • Duran-Frigola, Miquel, 1985-
  • Badia-I-Mompel, Pau
  • Pauls, Eduardo
  • Orozco, Modesto
  • Guitart Pla, Oriol
  • Alcalde, Víctor
  • Diaz, Víctor M.
  • Berenguer-Llergo, Antonio
  • Brun-Heath, Isabelle
  • Villegas, Núria
  • García de Herreros, Antonio
  • Aloy, Patrick, 1972-
Chemical descriptors encode the physicochemical and structural properties of small molecules, and they are at the core of chemoinformatics. The broad release of bioactivity data has prompted enriched representations of compounds, reaching beyond chemical structures and capturing their known biological properties. Unfortunately, bioactivity descriptors are not available for most small molecules, which limits their applicability to a few thousand well characterized compounds. Here we present a collection of deep neural networks able to infer bioactivity signatures for any compound of interest, even when little or no experimental information is available for them. Our signaturizers relate to bioactivities of 25 different types (including target profiles, cellular response and clinical outcomes) and can be used as drop-in replacements for chemical descriptors in day-to-day chemoinformatics tasks. Indeed, we illustrate how inferred bioactivity signatures are useful to navigate the chemical space in a biologically relevant manner, unveiling higher-order organization in natural product collections, and to enrich mostly uncharacterized chemical libraries for activity against the drug-orphan target Snail1. Moreover, we implement a battery of signature-activity relationship (SigAR) models and show a substantial improvement in performance, with respect to chemistry-based classifiers, across a series of biophysics and physiology activity prediction benchmarks., We would like to thank the SB&NB lab members for their support and helpful discussions. We are grateful to T.O. Botelho, I. Ramos, and C. Gonzalez for giving us access to the IRB Barcelona and Prestwick libraries. P.A. acknowledges the support of the Generalitat de Catalunya (RIS3CAT Emergents CECH: 001-P-001682 and VEIS: 001-P-001647), the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the European Commission (RiPCoN: 101003633). A.G.d.H. acknowledges support by Agencia Estatal de Investigación (AEI) and Fondos FEDER (PID2019-104698RB-I00).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Detecting similar binding pockets to enable systems polypharmacology

  • Duran Frigola, Miquel
  • Siragusa, Lydia
  • Ruppin, Eytan
  • Barril Alonso, Xavier
  • Cruciani, Gabriele
  • Aloy, Patrick, 1972-
In the era of systems biology, multi-target pharmacological strategies hold promise for tackling disease-related networks. In this regard, drug promiscuity may be leveraged to interfere with multiple receptors: the so-called polypharmacology of drugs can be anticipated by analyzing the similarity of binding sites across the proteome. Here, we perform a pairwise comparison of 90,000 putative binding pockets detected in 3,700 proteins, and find that 23,000 pairs of proteins have at least one similar cavity that could, in principle, accommodate similar ligands. By inspecting these pairs, we demonstrate how the detection of similar binding sites expands the space of opportunities for the rational design of drug polypharmacology. Finally, we illustrate how to leverage these opportunities in protein-protein interaction networks related to several therapeutic classes and tumor types, and in a genome-scale metabolic model of leukemia.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Residues coevolution guides the systematic identification of alternative functional conformations in proteins

  • Sfriso, Pedro
  • Duran Frigola, Miquel
  • Mosca, Roberto
  • Emperador, Agustí
  • Aloy, Patrick, 1972-
  • Orozco López, Modesto
We present here a new approach for the systematic identification of functionally relevant conformations in proteins. Our fully automated pipeline, based on discrete molecular dynamics enriched with coevolutionary information, is able to capture alternative conformational states in 76% of the proteins studied, providing key atomic details for understanding their function and mechanism of action. We also demonstrate that, given its sampling speed, our method is well suited to explore structural transitions in a high-throughput manner, and can be used to determine functional conformational transitions at the entire proteome level.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Residues coevolution guides the systematic identification of alternative functional conformations in proteins

  • Sfriso, Pedro
  • Duran Frigola, Miquel
  • Mosca, Roberto
  • Emperador, Agustí
  • Aloy, Patrick, 1972-
  • Orozco López, Modesto
We present here a new approach for the systematic identification of functionally relevant conformations in proteins. Our fully automated pipeline, based on discrete molecular dynamics enriched with coevolutionary information, is able to capture alternative conformational states in 76% of the proteins studied, providing key atomic details for understanding their function and mechanism of action. We also demonstrate that, given its sampling speed, our method is well suited to explore structural transitions in a high-throughput manner, and can be used to determine functional conformational transitions at the entire proteome level.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Detecting similar binding pockets to enable systems polypharmacology

  • Duran Frigola, Miquel
  • Siragusa, Lydia
  • Ruppin, Eytan
  • Barril Alonso, Xavier
  • Cruciani, Gabriele
  • Aloy, Patrick, 1972-
In the era of systems biology, multi-target pharmacological strategies hold promise for tackling disease-related networks. In this regard, drug promiscuity may be leveraged to interfere with multiple receptors: the so-called polypharmacology of drugs can be anticipated by analyzing the similarity of binding sites across the proteome. Here, we perform a pairwise comparison of 90,000 putative binding pockets detected in 3,700 proteins, and find that 23,000 pairs of proteins have at least one similar cavity that could, in principle, accommodate similar ligands. By inspecting these pairs, we demonstrate how the detection of similar binding sites expands the space of opportunities for the rational design of drug polypharmacology. Finally, we illustrate how to leverage these opportunities in protein-protein interaction networks related to several therapeutic classes and tumor types, and in a genome-scale metabolic model of leukemia.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel, 1985-
  • Gris-Oliver, Albert
  • Palafox, Marta
  • Scaltriti, Maurizio
  • Razavi, Pedram
  • Chandarlapaty, Sarat
  • Arribas, Joaquín
  • Bellet, Meritxell
  • Serra, Violeta
  • Aloy, Patrick, 1972-
Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients' progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling., Funding: L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the Generalitat de Catalunya (VEIS 001-P-001). V.S. is a recipient of a Miguel Servet grant from ISCIII (CPII19/00033) and receives funds from AGAUR (2017 SGR 540). The PDX program is supported by a GHD-Pink (FERO foundation) grant to V.S., A.G.-O. and M.P. received a FI-AGAUR and a Juan de la Cierva (MJCI-2015-25412) fellowship, respectively. M.S., P.R., and S.C. acknowledge the support of the NIH grants P30 CA008748, RO1CA190642
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Bioactivity descriptors for uncharacterized chemical compounds

  • Bertoni, Martino
  • Duran-Frigola, Miquel, 1985-
  • Badia-I-Mompel, Pau
  • Pauls, Eduardo
  • Orozco, Modesto
  • Guitart Pla, Oriol
  • Alcalde, Víctor
  • Diaz, Víctor M.
  • Berenguer-Llergo, Antonio
  • Brun-Heath, Isabelle
  • Villegas, Núria
  • García de Herreros, Antonio
  • Aloy, Patrick, 1972-
Chemical descriptors encode the physicochemical and structural properties of small molecules, and they are at the core of chemoinformatics. The broad release of bioactivity data has prompted enriched representations of compounds, reaching beyond chemical structures and capturing their known biological properties. Unfortunately, bioactivity descriptors are not available for most small molecules, which limits their applicability to a few thousand well characterized compounds. Here we present a collection of deep neural networks able to infer bioactivity signatures for any compound of interest, even when little or no experimental information is available for them. Our signaturizers relate to bioactivities of 25 different types (including target profiles, cellular response and clinical outcomes) and can be used as drop-in replacements for chemical descriptors in day-to-day chemoinformatics tasks. Indeed, we illustrate how inferred bioactivity signatures are useful to navigate the chemical space in a biologically relevant manner, unveiling higher-order organization in natural product collections, and to enrich mostly uncharacterized chemical libraries for activity against the drug-orphan target Snail1. Moreover, we implement a battery of signature-activity relationship (SigAR) models and show a substantial improvement in performance, with respect to chemistry-based classifiers, across a series of biophysics and physiology activity prediction benchmarks., We would like to thank the SB&NB lab members for their support and helpful discussions. We are grateful to T.O. Botelho, I. Ramos, and C. Gonzalez for giving us access to the IRB Barcelona and Prestwick libraries. P.A. acknowledges the support of the Generalitat de Catalunya (RIS3CAT Emergents CECH: 001-P-001682 and VEIS: 001-P-001647), the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the European Commission (RiPCoN: 101003633). A.G.d.H. acknowledges support by Agencia Estatal de Investigación (AEI) and Fondos FEDER (PID2019-104698RB-I00).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Encircling the regions of the pharmacogenomic landscape that determine drug response

  • Fernández Torras, Adrià
  • Duran-Frigola, Miquel, 1985-
  • Aloy, Patrick, 1972-
Background: The integration of large-scale drug sensitivity screens and genome-wide experiments is changing the field of pharmacogenomics, revealing molecular determinants of drug response without the need for previous knowledge about drug action. In particular, transcriptional signatures of drug sensitivity may guide drug repositioning, prioritize drug combinations, and point to new therapeutic biomarkers. However, the inherent complexity of transcriptional signatures, with thousands of differentially expressed genes, makes them hard to interpret, thus giving poor mechanistic insights and hampering translation to clinics. Methods: To simplify drug signatures, we have developed a network-based methodology to identify functionally coherent gene modules. Our strategy starts with the calculation of drug-gene correlations and is followed by a pathway-oriented filtering and a network-diffusion analysis across the interactome. Results: We apply our approach to 189 drugs tested in 671 cancer cell lines and observe a connection between gene expression levels of the modules and mechanisms of action of the drugs. Further, we characterize multiple aspects of the modules, including their functional categories, tissue-specificity, and prevalence in clinics. Finally, we prove the predictive capability of the modules and demonstrate how they can be used as gene sets in conventional enrichment analyses. Conclusions: Network biology strategies like module detection are able to digest the outcome of large-scale pharmacogenomic initiatives, thereby contributing to their interpretability and improving the characterization of the drugs screened., A.F-T. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R) and the European Research Council (SysPharmAD: 614944).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

In silico characterization of human prion-like proteins: beyond neurological diseases

  • Iglesias, Valentin
  • Paladin, Lisanna
  • Juan Blanco, Teresa, 1989-
  • Pallarès, Irantzu
  • Aloy, Patrick, 1972-
  • Tosatto, Silvio C.E.
  • Ventura, Salvador
Prion-like behavior has been in the spotlight since it was first associated with the onset of mammalian neurodegenerative diseases. However, a growing body of evidence suggests that this mechanism could be behind the regulation of processes such as transcription and translation in multiple species. Here, we perform a stringent computational survey to identify prion-like proteins in the human proteome. We detected 242 candidate polypeptides and computationally assessed their function, protein-protein interaction networks, tissular expression, and their link to disease. Human prion-like proteins constitute a subset of modular polypeptides broadly expressed across different cell types and tissues, significantly associated with disease, embedded in highly connected interaction networks, and involved in the flow of genetic information in the cell. Our analysis suggests that these proteins might play a relevant role not only in neurological disorders, but also in different types of cancer and viral infections., SV was supported by Ministerio de Economía y Competitividad (MINECO) (BIO2016-78310-R) and by ICREA, ICREA ACADEMIA 2015 to SV. PA was supported by MINECO (BIO2016-77038-R) and the European Research Council Consolidator grant, SysPharmAD (614944). TJ-B is a recipient of an FPI-SO fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel
  • Palafox Sánchez, Marta
  • Scaltriti, Maurizio
  • Razavi, Pedram
  • Arribas López, Joaquin Vicente
  • Serra Elizalde, Violeta
  • Gris Oliver, Albert
  • Bellet Ezquerra, Meritxell
Biomarcadores de respuesta a fármacos; Redes de co-ocurrencia de conductores; Oncología de precisión, Biomarcadors de resposta a fàrmacs; Xarxes de co-ocurrència de conductors; Oncologia de precisió, Drug-response biomarkers; Driver co-occurrence networks; Precision oncology, Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients’ progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling., L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the Generalitat de Catalunya (VEIS 001-P-001). V.S. is a recipient of a Miguel Servet grant from ISCIII (CPII19/00033) and receives funds from AGAUR (2017 SGR 540). The PDX program is supported by a GHD-Pink (FERO foundation) grant to V.S., A.G.-O. and M.P. received a FI-AGAUR and a Juan de la Cierva (MJCI-2015-25412) fellowship, respectively. M.S., P.R., and S.C. acknowledge the support of the NIH grants P30 CA008748, RO1CA190642, and the Breast Cancer Research Foundation. Additionally, P.R. receives funds from the Breast Cancer Alliance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In silico characterization of human prion-like proteins, beyond neurological diseases

  • Iglesias, Valentin|||0000-0002-6133-0869
  • Paladin, Lisanna
  • Juan Blanco, Teresa
  • Pallarès i Goitiz, Irantzu|||0000-0002-8205-2060
  • Aloy, Patrick|||0000-0002-3557-0236
  • Tosatto, Silvio|||0000-0003-4525-7793
  • Ventura, Salvador|||0000-0002-9652-6351
Prion-like behavior has been in the spotlight since it was first associated with the onset of mammalian neurodegenerative diseases. However, a growing body of evidence suggests that this mechanism could be behind the regulation of processes such as transcription and translation in multiple species. Here, we perform a stringent computational survey to identify prion-like proteins in the human proteome. We detected 242 candidate polypeptides and computationally assessed their function, protein-protein interaction networks, tissular expression, and their link to disease. Human prion-like proteins constitute a subset of modular polypeptides broadly expressed across different cell types and tissues, significantly associated with disease, embedded in highly connected interaction networks, and involved in the flow of genetic information in the cell. Our analysis suggests that these proteins might play a relevant role not only in neurological disorders, but also in different types of cancer and viral infections.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

  • Mateo, Lidia
  • Duran-Frigola, Miquel
  • Palafox Sánchez, Marta
  • Scaltriti, Maurizio
  • Razavi, Pedram
  • Arribas López, Joaquin Vicente
  • Serra Elizalde, Violeta
  • Gris Oliver, Albert
  • Bellet Ezquerra, Meritxell
Biomarcadores de respuesta a fármacos; Redes de co-ocurrencia de conductores; Oncología de precisión, Biomarcadors de resposta a fàrmacs; Xarxes de co-ocurrència de conductors; Oncologia de precisió, Drug-response biomarkers; Driver co-occurrence networks; Precision oncology, Identification of actionable genomic vulnerabilities is key to precision oncology. Utilizing a large-scale drug screening in patient-derived xenografts, we uncover driver gene alteration connections, derive driver co-occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug-response predictors attains an average balanced accuracy of 58% in a cross-validation setting, rising to 66% for a subset of high-confidence predictions. We experimentally validated 12 out of 14 predictions in mice and adapted our strategy to obtain drug-response models from patients’ progression-free survival data. Our strategy reveals links between oncogenic alterations, increasing the clinical impact of genomic profiling., L.M. is a recipient of an FPI fellowship. P.A. acknowledges the support of the Spanish Ministerio de Economía y Competitividad (BIO2016-77038-R), the European Research Council (SysPharmAD: 614944), and the Generalitat de Catalunya (VEIS 001-P-001). V.S. is a recipient of a Miguel Servet grant from ISCIII (CPII19/00033) and receives funds from AGAUR (2017 SGR 540). The PDX program is supported by a GHD-Pink (FERO foundation) grant to V.S., A.G.-O. and M.P. received a FI-AGAUR and a Juan de la Cierva (MJCI-2015-25412) fellowship, respectively. M.S., P.R., and S.C. acknowledge the support of the NIH grants P30 CA008748, RO1CA190642, and the Breast Cancer Research Foundation. Additionally, P.R. receives funds from the Breast Cancer Alliance.